NASDAQ : NUVL
Nuvalent, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 123.96 USD (At close: Jul 14, 2026) · Market cap 9.83B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Selling, General & Admin | 122.74M | 107.34M | 62.59M | 36.25M | 22.38M | 10.26M |
| Research & Development | 316.16M | 306.97M | 217.77M | 113.24M | 63.73M | 35.56M |
| Operating Expenses | 438.90M | 414.31M | 280.37M | 149.49M | 86.11M | 45.82M |
| Operating Income | -438.90M | -414.31M | -280.37M | -149.49M | -86.11M | -45.82M |
| Interest & Investment Income | 34.66M | 33.63M | 23.65M | 13.16M | 3.88M | 329.00K |
| Other Non Operating Income (Expenses) | -56.34M | -55.22M | -17.94M | -635.00K | ||
| EBT Excluding Unusual Items | -460.58M | -435.90M | -274.66M | -136.33M | -82.23M | -46.12M |
| Gain (Loss) on Sale of Investments | 11.11M | 11.11M | 14.67M | 10.11M | 373.00K | -215.00K |
| Pretax Income | -449.48M | -424.79M | -259.99M | -126.22M | -81.85M | -46.34M |
| Income Tax Expense | 596.00K | 585.00K | 764.00K | |||
| Net Income | -450.07M | -425.38M | -260.76M | -126.22M | -81.85M | -46.34M |
| Net Income to Common | -450.07M | -425.38M | -260.76M | -126.22M | -81.85M | -46.34M |
| Shares Outstanding (Basic) | 74.45M | 72.69M | 66.41M | 58.22M | 49.67M | 21.78M |
| Shares Outstanding (Diluted) | 74.45M | 72.69M | 66.41M | 58.22M | 49.67M | 21.78M |
| EPS (Basic) | -6.05 | -5.85 | -3.93 | -2.17 | -1.65 | -2.13 |
| EPS (Diluted) | -6.05 | -5.85 | -3.93 | -2.17 | -1.65 | -2.13 |
| EBIT | -438.90M | -414.31M | -280.37M | -149.49M | -86.11M | -45.82M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 159.73M | 261.75M | 145.69M | 335.39M | 241.81M | 68.53M |
| Short-Term Investments | 1.13B | 1.11B | 972.61M | 384.52M | 230.36M | 219.59M |
| Cash & Short-Term Investments | 1.29B | 1.37B | 1.12B | 719.90M | 472.16M | 288.11M |
| Prepaid Expenses | 20.46M | 20.47M | 14.15M | 6.58M | 5.83M | 2.52M |
| Total Current Assets | 1.31B | 1.39B | 1.13B | 726.49M | 477.99M | 290.63M |
| Other Long-Term Assets | 23.21M | 20.28M | 9.30M | 5.90M | 4.47M | 3.20M |
| Total Assets | 1.33B | 1.41B | 1.14B | 732.38M | 482.46M | 293.82M |
| Accounts Payable | 22.14M | 30.16M | 5.22M | 9.27M | 7.20M | 2.89M |
| Accrued Expenses | 58.91M | 61.01M | 48.80M | 22.55M | 12.29M | 5.89M |
| Total Current Liabilities | 81.05M | 91.17M | 54.02M | 31.82M | 19.48M | 8.79M |
| Other Long-Term Liabilities | 75.73M | 73.19M | 17.94M | |||
| Total Liabilities | 156.78M | 164.37M | 71.96M | 31.82M | 19.48M | 8.79M |
| Common Stock | 8.00K | 8.00K | 8.00K | 7.00K | 6.00K | 5.00K |
| Additional Paid-In Capital | 2.26B | 2.22B | 1.62B | 986.82M | 623.54M | 363.48M |
| Retained Earnings | -1.08B | -972.43M | -547.05M | -286.30M | -160.08M | -78.22M |
| Comprehensive Income & Other | -1.35M | 2.35M | -59.00K | 31.00K | -494.00K | -228.00K |
| Total Common Equity | 1.17B | 1.25B | 1.07B | 700.56M | 462.98M | 285.04M |
| Shareholders' Equity | 1.17B | 1.25B | 1.07B | 700.56M | 462.98M | 285.04M |
| Total Liabilities & Equity | 1.33B | 1.41B | 1.14B | 732.38M | 482.46M | 293.82M |
| Net Cash (Debt) | 1.29B | 1.37B | 1.12B | 719.90M | 472.16M | 288.11M |
| Net Cash Per Share | 17.29 | 18.87 | 16.84 | 12.36 | 9.51 | 13.23 |
| Filing Date Shares Outstanding | 79.00M | 78.62M | 71.60M | 64.07M | 56.70M | 48.31M |
| Total Common Shares Outstanding | 78.88M | 78.24M | 71.34M | 64.07M | 56.67M | 48.30M |
| Working Capital | 1.23B | 1.30B | 1.08B | 694.66M | 458.51M | 281.84M |
| Book Value Per Share | 14.89 | 15.96 | 14.99 | 10.94 | 8.17 | 5.90 |
| Tangible Book Value | 1.17B | 1.25B | 1.07B | 700.56M | 462.98M | 285.04M |
| Tangible Book Value Per Share | 14.89 | 15.96 | 14.99 | 10.94 | 8.17 | 5.90 |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Net Income | -450.07M | -425.38M | -260.76M | -126.22M | -81.85M | -46.34M |
| Loss (Gain) From Sale of Investments | -8.65M | -11.11M | -14.67M | -10.11M | -373.00K | 215.00K |
| Stock-Based Compensation | 95.00M | 86.50M | 60.58M | 25.56M | 10.32M | 3.55M |
| Other Operating Activities | 56.79M | 55.56M | 17.94M | 631.00K | ||
| Change in Accounts Payable | -4.03M | 24.60M | -4.05M | 2.17M | 4.21M | 1.64M |
| Change in Other Net Operating Assets | -1.82M | -5.39M | 15.89M | 8.86M | 2.72M | 300.00K |
| Operating Cash Flow | -312.79M | -275.21M | -185.06M | -99.74M | -64.97M | -40.00M |
| Investment in Securities | -168.91M | -124.08M | -573.51M | -143.53M | -10.66M | -220.03M |
| Investing Cash Flow | -168.91M | -124.08M | -573.51M | -143.53M | -10.66M | -220.03M |
| Long-Term Debt Issued | 284.00K | |||||
| Net Debt Issued (Repaid) | 284.00K | |||||
| Issuance of Common Stock | 521.30M | 515.72M | 569.99M | 338.48M | 250.47M | 177.28M |
| Other Financing Activities | -710.00K | -382.00K | -1.10M | -1.63M | -1.55M | -4.00M |
| Financing Cash Flow | 520.59M | 515.34M | 568.88M | 336.85M | 248.92M | 318.22M |
| Net Cash Flow | 38.90M | 116.05M | -189.70M | 93.58M | 173.28M | 58.19M |
| Levered Free Cash Flow | -180.43M | -141.62M | -100.02M | -56.28M | -36.11M | -22.88M |
| Unlevered Free Cash Flow | -180.43M | -141.62M | -100.02M | -56.28M | -36.11M | -22.88M |
| Change in Working Capital | -5.85M | 19.21M | 11.84M | 11.03M | 6.93M | 1.94M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 9.83B | 7.81B | 5.56B | 4.61B | 1.68B | 919.33M |
| Enterprise Value | 8.55B | 6.87B | 4.39B | 4.20B | 1.44B | 616.90M |
| Last Close Price | 100.59 | 78.28 | 73.59 | 29.78 | 19.04 | |
| PB Ratio | 8.33 | 6.26 | 5.20 | 6.58 | 3.63 | 3.23 |
| P/TBV Ratio | 8.37 | 6.26 | 5.20 | 6.58 | 3.63 | 3.23 |
| Net Debt / Equity Ratio | -1.10 | -1.10 | -1.04 | -1.03 | -1.02 | -1.01 |
| Quick Ratio | 15.88 | 15.05 | 20.70 | 22.62 | 24.24 | 32.79 |
| Current Ratio | 16.14 | 15.27 | 20.96 | 22.83 | 24.54 | 33.08 |
| Return on Equity (ROE) | -41.19% | -36.70% | -29.46% | -21.70% | -21.89% | -32.06% |
| Return on Assets (ROA) | -22.51% | -20.27% | -18.70% | -15.38% | -13.87% | -18.81% |
| Return on Capital Employed (ROCE) | -35.10% | -31.40% | -25.80% | -21.30% | -18.60% | -16.10% |
| Earnings Yield | -4.58% | -5.45% | -4.69% | -2.74% | -4.87% | -5.04% |
| Buyback Yield / Dilution | -9.05% | -9.45% | -14.06% | -17.22% | -128.01% | -659.75% |